- Home
- APLM vs FRSX Comparison
APLM vs FRSX Comparison
Compare APLM & FRSX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APLM
- FRSX
- Stock Information
- Founded
- APLM 2016
- FRSX N/A
- Country
- APLM United States
- FRSX Israel
- Employees
- APLM N/A
- FRSX N/A
- Industry
- APLM Blank Checks
- FRSX Computer Software: Prepackaged Software
- Sector
- APLM Finance
- FRSX Technology
- Exchange
- APLM Nasdaq
- FRSX Nasdaq
- Market Cap
- APLM 6.1M
- FRSX 7.0M
- IPO Year
- APLM N/A
- FRSX 2017
- Fundamental
- Price
- APLM $5.48
- FRSX $2.42
- Analyst Decision
- APLM
- FRSX
- Analyst Count
- APLM 0
- FRSX 0
- Target Price
- APLM N/A
- FRSX N/A
- AVG Volume (30 Days)
- APLM 33.5K
- FRSX 44.0K
- Earning Date
- APLM 09-16-2025
- FRSX 09-21-2025
- Dividend Yield
- APLM N/A
- FRSX N/A
- EPS Growth
- APLM N/A
- FRSX N/A
- EPS
- APLM N/A
- FRSX N/A
- Revenue
- APLM $198,000.00
- FRSX $452,000.00
- Revenue This Year
- APLM $415.15
- FRSX N/A
- Revenue Next Year
- APLM N/A
- FRSX N/A
- P/E Ratio
- APLM N/A
- FRSX N/A
- Revenue Growth
- APLM N/A
- FRSX N/A
- 52 Week Low
- APLM $3.66
- FRSX $2.17
- 52 Week High
- APLM $35.98
- FRSX $18.41
- Technical
- Relative Strength Index (RSI)
- APLM 49.97
- FRSX 42.63
- Support Level
- APLM $3.66
- FRSX $2.27
- Resistance Level
- APLM $6.37
- FRSX $2.52
- Average True Range (ATR)
- APLM 0.54
- FRSX 0.21
- MACD
- APLM -0.10
- FRSX 0.03
- Stochastic Oscillator
- APLM 67.17
- FRSX 42.52
About APLM Apollomics Inc.
Apollomics Inc is an clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia.
About FRSX Foresight Autonomous Holdings Ltd.
Foresight Autonomous Holdings Ltd is a technology company engaged in the design, development and commercialization of vision systems for the automotive industry. The company develops both in-line-of-sight vision systems and beyond-line-of-sight cellular-based applications through its wholly-owned subsidiaries. Its systems are designed to improve driving safety by enabling accurate and reliable threat detection while ensuring the lowest rates of false alerts. Foresight is pursuing several markets and believes its modern systems will revolutionize automotive safety by providing an automotive-grade, cost-effective platform.